Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for cancer patients. Its product pipeline includes EOS-850, a small molecule antagonist of the adenosine A2a receptor; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains. The company was founded in 2011 and is based in Cambridge, Massachusetts with an additional location in Gosselies, Belgium.